Diligence memo · auto-generated · as of July 2, 2026
Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Endonovo Therapeutics, Inc. operates in Biotechnology, based in WOODLAND HILLS.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Endonovo Therapeutics, Inc. has raised $1.7M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $700K on 2017-12-12.
Most recent recorded round closed around 2019-10-31.
Valuation (modeled)modeled
Provath models Endonovo Therapeutics, Inc. at approximately $12M (range $120K–$141M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 6.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 26% of Biotechnology peers (4293 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.